Femasys reports Q1 net income of $846K; sales up 24.5%; cash sufficient into Q3 2026

FEMASYS INC

2026-Q1 EPS reported $0.00 vs consensus -$0.09 ▲ beat (+100.0%)

Net income $846,100 ($0.00 per diluted share) vs net loss $5.9M ($0.23 loss) in prior year; net income includes $5.2M in gains from fair value changes.
Sales rose 24.5% to $424,889, driven by FemBloc sales; R&D expenses down 55.9% to $1.31M.
Cash $5.4M as of March 31; company expects funding into Q3 2026 based on current operating plan.
Advanced FemaSeed Complete commercialization; initiated FINALE pivotal trial for FemBloc non-surgical birth control.
Appointed John Canning as COO; added Kenneth D. Eichenbaum to board; MDSAP certification for FemBloc.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

FEMASYS INC reported quarter ended March 31, 2026 results: revenue $424,889, net income $846,100, or $0.00 per basic and diluted share, EPS $0.00 per basic and diluted share.

Period: quarter ended March 31, 2026
Revenue: $424,889
Net income: $846,100, or $0.00 per basic and diluted share
EPS: $0.00 per basic and diluted share
Result: reported results

Exact text from the filing

addressing critical unmet needs with safe, technologically advanced products.” Financial Results for Quarter Ended March 31, 2026 • Sales increased by $83,625, or 24.5%, to $424,889 in 2026 from $341,264 in 2025, primarily due to sales of FemBloc. • Research and development expenses decreased by $1,659,071, or 55.9%, to $1,309,401 in 2026 compared to

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-26-020059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.